Artificially Reprogrammed Macrophages as Tumor-Tropic Immunosuppression-Resistant Biologics to Realize Therapeutics Production and Immune Activation

© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 31(2019), 15 vom: 17. Apr., Seite e1807211
1. Verfasser: Li, Chu-Xin (VerfasserIn)
Weitere Verfasser: Zhang, Yu, Dong, Xue, Zhang, Lu, Liu, Miao-Deng, Li, Bin, Zhang, Ming-Kang, Feng, Jun, Zhang, Xian-Zheng
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2019
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article artificially reprogrammed cell cell therapeutic immune recovery immunosuppression resistance tumor immunotherapy Antigens, Neoplasm Magnetite Nanoparticles
LEADER 01000naa a22002652 4500
001 NLM294279016
003 DE-627
005 20231225081134.0
007 cr uuu---uuuuu
008 231225s2019 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.201807211  |2 doi 
028 5 2 |a pubmed24n0980.xml 
035 |a (DE-627)NLM294279016 
035 |a (NLM)30803083 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Li, Chu-Xin  |e verfasserin  |4 aut 
245 1 0 |a Artificially Reprogrammed Macrophages as Tumor-Tropic Immunosuppression-Resistant Biologics to Realize Therapeutics Production and Immune Activation 
264 1 |c 2019 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 31.07.2019 
500 |a Date Revised 30.09.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
520 |a To engineer patient-derived cells into therapy-purposed biologics is a promising solution to realize personalized treatments. Without using gene-editing technology, a live cell-typed therapeutic is engineered for tumor treatment by artificially reprogramming macrophages with hyaluronic acid-decorated superparamagnetic iron oxide nanoparticles (HIONs). This nanoparticle-assisted cell-reprogramming strategy demonstrates profound advantages, due to the combined contributions from the biological regulation of HIONs and the intrinsic nature of macrophages. Firstly, the reprogrammed macrophages present a substantial improvement in their innate capabilities, such as more effective tumor targeting and more efficient generation of bioactive components (e.g., reactive oxygen species, bioactive cytokines) to suppress tumor growth. Furthermore, this cell therapeutic exhibits cytostatic/proapoptotic effects specific to cancer cells. Secondly, HIONs enable macrophages more resistant to the intratumoral immunosuppressive environment. Thirdly, the macrophages are endowed with a strong ability to prime in situ protumoral M2 macrophages into antitumor M1 phenotype in a paracrine-like manner. Consequently, a synergistic tumor-inhibition effect is achieved. This study shows that engineering nanomaterial-reprogrammed live cells as therapeutic biologics may be a more preferable option to the commonly used approaches where nanomaterials are administrated to induce bioresponse of certain cells in vivo 
650 4 |a Journal Article 
650 4 |a artificially reprogrammed cell 
650 4 |a cell therapeutic 
650 4 |a immune recovery 
650 4 |a immunosuppression resistance 
650 4 |a tumor immunotherapy 
650 7 |a Antigens, Neoplasm  |2 NLM 
650 7 |a Magnetite Nanoparticles  |2 NLM 
700 1 |a Zhang, Yu  |e verfasserin  |4 aut 
700 1 |a Dong, Xue  |e verfasserin  |4 aut 
700 1 |a Zhang, Lu  |e verfasserin  |4 aut 
700 1 |a Liu, Miao-Deng  |e verfasserin  |4 aut 
700 1 |a Li, Bin  |e verfasserin  |4 aut 
700 1 |a Zhang, Ming-Kang  |e verfasserin  |4 aut 
700 1 |a Feng, Jun  |e verfasserin  |4 aut 
700 1 |a Zhang, Xian-Zheng  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 31(2019), 15 vom: 17. Apr., Seite e1807211  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnns 
773 1 8 |g volume:31  |g year:2019  |g number:15  |g day:17  |g month:04  |g pages:e1807211 
856 4 0 |u http://dx.doi.org/10.1002/adma.201807211  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 31  |j 2019  |e 15  |b 17  |c 04  |h e1807211